Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income on an organic operational basis.</li><li>The results were fueled by strong performances in both international and U.S. markets, with international revenue growing by 6% and U.S. revenue by 3% when excluding divestitures.</li><li>However, this growth was moderated compared to previous quarters due to various market dynamics and challenges.</li></ul>

Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income on an organic operational basis.The results were fueled by strong performances in both international and U.S. markets, with international revenue growing by 6% and U.S. revenue by 3% when excluding divestitures.However, this growth was moderated compared to previous quarters due to various market dynamics and challenges.

Zoetis Surges Forward as Librela Stabilizes—Signaling a Major Comeback in 2026!

<ul><li>In the second quarter of 2025, Zoetis reported robust financial results, underscoring the strength and resilience of its portfolio across multiple markets.</li><li>The company achieved an organic operational revenue growth of 8% and a 10% increase in adjusted net income, reflecting effective cost management and operational efficiency.</li><li>One of the key highlights was the International segment, which experienced a 9% organic operational revenue growth, indicating Zoetis's ability to leverage trends expanding regional markets.</li></ul>

In the second quarter of 2025, Zoetis reported robust financial results, underscoring the strength and resilience of its portfolio across multiple markets.The company achieved an organic operational revenue growth of 8% and a 10% increase in adjusted net income, reflecting effective cost management and operational efficiency.One of the key highlights was the International segment, which experienced a 9% organic operational revenue growth, indicating Zoetis's ability to leverage trends expanding regional markets.

Zoetis Is Looking To Capitalize On The Triple Combo Market—Can The Stock Move Past Its Flat Trajectory?

<ul><li>Zoetis Inc. recently held its first-quarter 2025 financial results presentation, where senior executives highlighted the company's performance amidst a challenging economic landscape marked by geopolitical and regulatory uncertainties.</li><li>Zoetis reported a strong 9% growth in organic operational revenue, driven largely by the International segment, which grew by 11%, while the U.S. segment grew by 6% when excluding its Medicated Feed Additives (MFA) divestiture.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Zoetis Inc. recently held its first-quarter 2025 financial results presentation, where senior executives highlighted the company's performance amidst a challenging economic landscape marked by geopolitical and regulatory uncertainties.Zoetis reported a strong 9% growth in organic operational revenue, driven largely by the International segment, which grew by 11%, while the U.S. segment grew by 6% when excluding its Medicated Feed Additives (MFA) divestiture.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Zoetis Inc.: Focus On Adaptation to Market Channels & Consumer Preferences To Sustain Growth Across Its Diverse Portfolio!

<ul><li>Zoetis reported strong financial results for its fiscal year 2024, reaching the high end of its guidance, largely driven by double-digit operational revenue growth of 11%.</li><li>The company's robust performance is attributed to its formidable portfolio spanning both the Companion Animal and Livestock segments.</li><li>For the U.S., revenue surged by 11%, while international revenue saw a 10% operational increase, demonstrating the company's capability to navigate a competitive landscape effectively.</li></ul>

Zoetis reported strong financial results for its fiscal year 2024, reaching the high end of its guidance, largely driven by double-digit operational revenue growth of 11%.The company's robust performance is attributed to its formidable portfolio spanning both the Companion Animal and Livestock segments.For the U.S., revenue surged by 11%, while international revenue saw a 10% operational increase, demonstrating the company's capability to navigate a competitive landscape effectively.

Zoetis Inc.: Double-Digit Growth in Major Franchises Propelling Our 'Buy' Rating!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported 2Q25 result, with double-digit revenue growth and decline in operating and net profit. Continued strong sales of prescription drug business remained the key driver.</li>
<li>During 2Q25, domestic outpatient prescription sales of K-CAB increased 14% YoY to KRW53B. Next major trigger for K-CAB will be the U.S. filing for both EE and NERD in 4Q25.</li>
<li>Recently, the company’s investigational new drug IN-115314 advances to Phase 3 trial for the treatment of atopic dermatitis in dogs. If approved, IN-115314 has blockbuster revenue potential.</li>
</ul>



HK inno.N (195940 KS) reported 2Q25 result, with double-digit revenue growth and decline in operating and net profit. Continued strong sales of prescription drug business remained the key driver.
During 2Q25, domestic outpatient prescription sales of K-CAB increased 14% YoY to KRW53B. Next major trigger for K-CAB will be the U.S. filing for both EE and NERD in 4Q25.
Recently, the company’s investigational new drug IN-115314 advances to Phase 3 trial for the treatment of atopic dermatitis in dogs. If approved, IN-115314 has blockbuster revenue potential.


HK Inno.N (195940 KS): Mixed 2Q Result; Pipeline Progress to Maintain Positive Momentum

United States

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets its products in North America, Europe, Africa, Asia, Australia, and Latin America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zoetis (ZTS UN)

Zoetis Surges Forward as Librela Stabilizes—Signaling a Major Comeback in 2026!

Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income...

Baptista Research

Zoetis Is Looking To Capitalize On The Triple Combo Market—Can The Stock Move Past Its Flat Trajectory?

In the second quarter of 2025, Zoetis reported robust financial results, underscoring the strength and resilience of its portfolio across multiple...

Baptista Research

Zoetis Inc.: Focus On Adaptation to Market Channels & Consumer Preferences To Sustain Growth Across Its Diverse Portfolio!

Zoetis Inc. recently held its first-quarter 2025 financial results presentation, where senior executives highlighted the company's performance...

Baptista Research

Zoetis Inc.: Double-Digit Growth in Major Franchises Propelling Our 'Buy' Rating!

Zoetis reported strong financial results for its fiscal year 2024, reaching the high end of its guidance, largely driven by double-digit...

Baptista Research

HK Inno.N (195940 KS): Mixed 2Q Result; Pipeline Progress to Maintain Positive Momentum

HK inno sees double-digit revenue growth in 2Q25, driven by strong sales of prescription drugs. Profit decline seems temporary drag. Next major...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Zoetis Surges Forward as Librela Stabilizes—Signaling a Major Comeback in 2026!

Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income...

Baptista Research

Zoetis Is Looking To Capitalize On The Triple Combo Market—Can The Stock Move Past Its Flat Trajectory?

In the second quarter of 2025, Zoetis reported robust financial results, underscoring the strength and resilience of its portfolio across multiple...

Baptista Research

Zoetis Inc.: Focus On Adaptation to Market Channels & Consumer Preferences To Sustain Growth Across Its Diverse Portfolio!

Zoetis Inc. recently held its first-quarter 2025 financial results presentation, where senior executives highlighted the company's performance...

Baptista Research

Zoetis Inc.: Double-Digit Growth in Major Franchises Propelling Our 'Buy' Rating!

Zoetis reported strong financial results for its fiscal year 2024, reaching the high end of its guidance, largely driven by double-digit...

Baptista Research

HK Inno.N (195940 KS): Mixed 2Q Result; Pipeline Progress to Maintain Positive Momentum

​HK inno sees double-digit revenue growth in 2Q25, driven by strong sales of prescription drugs. Profit decline seems temporary drag. Next major...

Tina Banerjee

HK inno sees double-digit revenue growth in 2Q25, driven by strong sales of prescription drugs. Profit decline seems temporary drag. Next major...